ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
Bruna Pellini1,2, Aadel A Chaudhuri3,4,5,6,7,8
1Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida.
Abstract:
Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes. See related article by Sivapalan et al., p. 2310.
